Evidence map›Paper›PMID 33149567›Full record

ReviewInternational journal of chronic obstructive pulmonary disease2020

Dual Bronchodilator in the Era of Triple Therapy.

Andriana I Papaioannou, Stelios Loukides, Petros Bakakos, Epameinondas N Kosmas, Nikoletta Rovina, Paschalis Steiropoulos, Evangellia Fouka, Georgios Hillas, Georgios Patentalakis, Marousa Kouvela and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of chronic obstructive pulmonary disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. The Impact of the Pay-for-Performance Program on the Outcome of COPD Patients in Taiwan After One Year.International journal of chronic obstructive pulmonary disease · 2022
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Andriana I Papaioannou2nd Respiratory Medicine Department, University of Athens, "Attikon" University Hospital, Athens, Greece.ORCID 0000-0001-9708-3241
Stelios Loukides2nd Respiratory Medicine Department, University of Athens, "Attikon" University Hospital, Athens, Greece.ORCID 0000-0002-4278-9922
Petros Bakakos1st Respiratory Medicine Department, University of Athens, "Sotiria" Chest Hospital, Athens, Greece.
Epameinondas N KosmasPNOH Pulmonary Clinic, Metropolitan Hospital, Athens, Greece.
Nikoletta Rovina1st Respiratory Medicine Department, University of Athens, "Sotiria" Chest Hospital, Athens, Greece.ORCID 0000-0003-0138-5582
Paschalis SteiropoulosDepartment of Respiratory Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.ORCID 0000-0001-7121-6253
Evangellia FoukaRespiratory Medicine Department, Aristotle University of Thessaloniki, G Papanikolaou Hospital, Thessaloniki, Greece.ORCID 0000-0003-4456-8987
Georgios Hillas5th Respiratory Medicine Department, Sotiria Chest Hospital, Athens, Greece.
Georgios Patentalakis3rd Department of Medicine, Athens Medical School, Athens, Greece.
Marousa Kouvela3rd Department of Medicine, Athens Medical School, Athens, Greece.ORCID 0000-0003-3002-9851
Nikos TzanakisDepartment of Thoracic Medicine, Faculty of Medicine, University of Crete, Crete, Greece.
National and Kapodistrian University of Athens · GRAthens Medical Center · GRAristotle University of Thessaloniki · GRDemocritus University of Thrace · GRMetropolitan Hospital · GRSotiria General Hospital · GRUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacological medications used for the treatment of COPD patients have increased significantly. Long-acting bronchodilators have been recognized as the mainstay of the treatment of stable COPD, while ICS are usually added in patients with COPD who experience exacerbations, despite bronchodilator treatment. In the latest years, several studies have been published showing the beneficial effect of adding ICS on dual bronchodilation in patients suffering from more severe disease comparing triple therapy with several therapeutic regiments including dual bronchodilation and providing a message that this triple therapy might be more appropriate for COPD patients. However, not all COPD patients have a desirable response to ICS treatment while long-term ICS use in COPD is associated with several side effects. In this report, we aimed to provide a review of the current knowledge on the importance of dual bronchodilation on COPD patients and to compare its use with triple therapy, by covering a wide spectrum of topics. Finally, we propose an algorithm on performing treatment step up from dual bronchodilation to triple therapy and step down from triple to double bronchodilation considering the current evidence.

Indexed as

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsDrug Therapy, CombinationHumansAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator Agentschronic obstructive pulmonary diseasedual bronchodilationinhaled corticosteroidstriple therapy

Identifiers

PMID33149567
PMCPMC7604249
OpenAlexW3096169406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.